AKT1 and colorectal cancer: It has been previously reported that in lung, prostate and colorectal cancer, the additive growth‐inhibitory effects of growth hormone‐releasing hormone (GHRH) antagonists plus cisplatin in vitro and in vivo are most likely due to the suppression by antagonist of PI3K/Akt activity.